Results 121 to 130 of about 4,422 (206)

Patient characteristics associated with 17-alpha hydroxyprogesterone caproate use among a high-risk cohort. [PDF]

Am J Obstet Gynecol, 2016
Turitz AL, Bastek JA, Purisch SE, Elovitz MA, Levine LD.   +4 more
europepmc   +1 more source

Vaginal administration of 17-alpha hydroxyprogesterone caproate appears to be safe in non-pregnant female rats and rabbits. [PDF]

Xenobiotica
Shaik IH, Chaphekar N, Vasudevan V, Alshabi A, AlOwaifeer A, Zhao W, Caritis S, Venkataramanan R.   +7 more
europepmc   +1 more source

The end is where we start from: withdrawal of 17-alpha hydroxyprogesterone caproate to prevent recurrent preterm birth. [PDF]

Am J Obstet Gynecol
Nelson DB, Herrera CL, McIntire DD, Cunningham FG.   +3 more
europepmc   +1 more source

Evaluation the effect of 17-alpha hydroxyprogesterone caproate on gestational diabetes mellitus in pregnant women at risk for preterm birth. [PDF]

Adv Biomed Res, 2015
Rouholamin S, Zarean E, Sadeghi L.
europepmc   +1 more source

Transient Pseudohypoaldosteronism due to Urinary Tract Infection in Infancy: A Report of 4 Cases [PDF]

, 2009
Radha Nandagopal, Priya Vaidyanathan, Paul Kaplowitz   +2 more
core   +1 more source

Epigenetic Regulation of the Nitric Oxide Pathway, 17-α Hydroxyprogesterone Caproate, and Recurrent Preterm Birth. [PDF]

Am J Perinatol, 2018
Manuck TA, Smeester L, Martin EM, Tomlinson MS, Smith C, Varner MW, Fry RC.   +6 more
europepmc   +1 more source

Measurement of betamethasone concentration in maternal serum treated for fetal lung maturity; Is it feasible? [PDF]

, 2016

core   +1 more source

Utilization, Cost, and Outcome of Branded vs Compounded 17-Alpha Hydroxyprogesterone Caproate in Prevention of Preterm Birth.

JAMA Intern Med, 2017
Fried I, Beam AL, Kohane IS, Palmer NP.
europepmc   +1 more source

17 Alpha-hydroxyprogesterone caproate for preterm prevention: issues in subgroup analysis [PDF]

American Journal of Obstetrics and Gynecology, 2016
openaire   +2 more sources